BioPharma Dive April 22, 2024
The deal is one of several recent collaborations involving small molecule drugs that modify RNA.
Dive Brief:
- French pharmaceutical company Ipsen will work with privately held biotechnology company Skyhawk Therapeutics to make small molecule drugs that modify RNA.
- Through a collaboration announced Monday, Ipsen and Skyhawk plan to develop multiple RNA-targeting medicines for rare neurological diseases. Ipsen has an option to acquire two for an undisclosed sum and could pay Skyhawk as much as $1.8 billion if certain milestones are met.
- The alliance is the latest industry collaboration focused on RNA-targeting pills, an increasingly popular area of drug research. Several startups, including Skyhawk, say the approach can help access disease targets previously thought to be “undruggable,” though much of...
Today's Sponsors
Today's Sponsor